2. Pang D, Thompson DNP. Embryology, classification, and surgical management of bony malformations of the craniovertebral junction. Adv Tech Stand Neurosurg 2014;40:19-109.
6. Cremers MJ, Bol E, de Roos F, et al. Risk of sports activities in children with Down’s syndrome and atlantoaxial instability. Lancet 1993;342:511-4.
9. Williams N, Narducci A, Eastwood DM, et al. An evidence-based approach to the management of children with morquio a syndrome presenting with craniocervical pathology. Spine (Phila Pa 1976) 2018;43:E1443-53.
10. Giangiobbe S, Caraffi SG, Ivanovski I, et al. Expanding the phenotype of WIEDEMANN‐STEINER syndrome: craniovertebral junction anomalies. Am J Med Genet 2020;182:2877-86.
12. Chauhan AK, Chandra PS, Goyal N, et al. Weak ligaments and sloping joints: a new hypothesis for development of congenital atlantoaxial dislocation and basilar invagination. Neurospine 2020;17:843-56.
14. Marquardt A, Stöhr H, Passmore LA, et al. Mutations in a novel gene, VMD2, encoding a protein of unknown properties cause juvenile-onset vitelliform macular dystrophy (Best’s disease). Hum Mol Genet 1998;7:1517-25.
15. Schatz P, Klar J, Andréasson S, et al. Variant phenotype of best vitelliform macular dystrophy associated with compound heterozygous mutations in VMD2. Ophthalmic Genet 2006;27:51-6.
20. Westerfield M. The zebrafish book. A guide for the laboratory use of zebrafish (Danio rerio). 4th ed. Eugene (OR): Univ. of Oregon Press; 2000.
21. Kimmel CB, Ballard WW, Kimmel SR, et al. Stages of embryonic development of the zebrafish. Dev Dyn 1995;203:253-310.
22. Park HC, Kim CH, Bae YK, et al. Analysis of upstream elements in the HuC promoter leads to the establishment of transgenic zebrafish with fluorescent neurons. Dev Biol 2000;227:279-93.
24. Wittström E, Ponjavic V, Bondeson ML, et al. Anterior segment abnormalities and angle-closure glaucoma in a family with a mutation in the BEST1 gene and best vitelliform macular dystrophy. Ophthalmic Genet 2011;32:217-27.
26. Yardley J, Leroy BP, Hart-Holden N, et al. Mutations of VMD2 splicing regulators cause nanophthalmos and autosomal dominant vitreoretinochoroidopathy (ADVIRC). Invest Ophthalmol Vis Sci 2004;45:3683-9.
32. Esumi N, Kachi S, Campochiaro PA, et al. VMD2 promoter requires two proximal E-box sites for its activity in vivo and is regulated by the MITF-TFE family. J Biol Chem 2007;282:1838-50.